{
  "burden_class": "EXTENSIVE",
  "burden_score": 0.7775280682546419,
  "clinical_notes": "CA-125 of 2842.0 U/mL indicates EXTENSIVE disease burden (>1,000). CA-125 is highly trackable and suitable for response monitoring. Complete response target: <35 U/mL. Additional therapy cycles likely needed.",
  "forecast": {
    "baseline_inferred_from_current": true,
    "baseline_inferred_note": "No explicit baseline provided and treatment not started; using current CA-125 as baseline for cycle milestone targets.",
    "complete_response_target": 35,
    "complete_response_target_unit": "U/mL",
    "cycle3_expected_drop_percent": 70,
    "cycle3_expected_value": 852.6,
    "cycle6_expected_drop_percent": 90,
    "cycle6_expected_value": 284.2
  },
  "monitoring_strategy": {
    "frequency": "every_2_weeks",
    "method": "Serum CA-125 (U/mL)",
    "rationale": "High baseline; track any changes before treatment",
    "timing": "Until treatment initiation"
  },
  "provenance": {
    "analyzed_at": "2026-02-14T04:24:33.408268",
    "baseline_inferred_from_current": true,
    "data_sources": [
      "GOG-218",
      "ICON7",
      "NCCN Guidelines v2024"
    ],
    "expectations": {
      "complete_response_threshold": 35,
      "cycle3_drop_percent": 70,
      "cycle6_drop_percent": 90,
      "resistance_threshold_percent": 50
    },
    "method": "ca125_intelligence_v1",
    "run_id": "ca125_1771061073",
    "thresholds": {
      "EXTENSIVE": [
        1000,
        "Infinity"
      ],
      "MINIMAL": [
        0,
        100
      ],
      "MODERATE": [
        100,
        500
      ],
      "SIGNIFICANT": [
        500,
        1000
      ]
    }
  },
  "resistance_signals": []
}
